International journal of MS care最新文献

{"title":"Using an Intervention Mapping Approach to Improve Adherence to Disease-Modifying Treatment in Multiple Sclerosis.","authors":"Efrat Neter,&nbsp;Ariel Miller","doi":"10.7224/1537-2073.2022-018","DOIUrl":"10.7224/1537-2073.2022-018","url":null,"abstract":"<p><strong>Background: </strong>Up to 50% of individuals with multiple sclerosis (MS) who are prescribed disease-modifying treatments (DMTs) do not take them as advised. Although many studies report on DMT adherence rate, few studies report on interventions involving individuals with MS. The current paper describes the development of an intervention aimed at improving adherence to DMTs among identified nonadherent individuals with MS.</p><p><strong>Methods: </strong>An intervention was developed using an Intervention Mapping approach, recommendations from reviews on medication adherence, and input from individuals with MS. Its content was determined by theories of health behavior (specifically, a perceptions and practicalities approach), empirical evidence collected among the specific target population (an observational \"needs assessment\" stage [n = 186]), and other studies.</p><p><strong>Results: </strong>A personalized intervention was tailored to the reasons for nonadherence, uncovered during the observational needs assessment stage, to be delivered sequentially by a neurologist and a psychologist. After the intervention objectives were identified, components of the intervention were set: psychoeducation and ways of coping with adverse effects; modification of unhelpful treatment beliefs (such modifications were found predictive of adherence in the observational phase of the study); improving confidence and self-efficacy; and developing strategies for remembering to take DMTs. These components were embedded within motivational interviewing.</p><p><strong>Conclusions: </strong>Intervention Mapping was useful in developing an intervention grounded both in the theoretical approach of perceptions and practicalities and in empirical evidence from the literature and the target sample; concurrently, identifying determinants that the intervention did not address. The effectiveness of the intervention-which could potentially improve adherence among individuals with MS-needs to be examined.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"206-213"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503812/pdf/i1537-2073-25-5-206.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Sickness/Serum Sickness-like Reactions Following Ocrelizumab Infusion in 2 Patients With Multiple Sclerosis.","authors":"Nicole Bou Rjeily,&nbsp;Bardia Nourbakhsh,&nbsp;Ellen M Mowry","doi":"10.7224/1537-2073.2022-080","DOIUrl":"10.7224/1537-2073.2022-080","url":null,"abstract":"<p><p>Serum sickness (SS) is a rare hypersensitivity reaction that can occur with monoclonal antibodies, and only 1 case of SS has been reported with ocrelizumab. We describe 2 patients with multiple sclerosis (MS) who developed SS/SS-like reactions (SSLRs) following ocrelizumab infusions. A man, aged 45 years, and a woman, aged 59 years, both with primary progressive MS, developed generalized weakness and arthralgias following their ocrelizumab infusions. Brain and spinal cord MRIs revealed no new or enhancing demyelinating lesions in both cases. They both had elevated inflammatory markers and negative infectious workups. They were subsequently treated for presumed SS with a steroid taper (and with potent anti-inflammatories in the second case), and symptoms improved dramatically after a few days. These cases suggest that SS/SSLRs should be suspected in a patient with new-onset arthralgia following ocrelizumab infusion who has an otherwise negative workup and rapid response to steroids.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"196-198"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503817/pdf/i1537-2073-25-5-196.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Disease-Modifying Therapy Adherence and Persistence in Multiple Sclerosis: A Scoping Literature Review.","authors":"Aliza Bitton Ben-Zacharia, Bryan Walker, Amy Perrin Ross, Carlo Tornatore, Natalie C Edwards, Yvette Lipman, Amy L Phillips","doi":"10.7224/1537-2073.2021-139","DOIUrl":"10.7224/1537-2073.2021-139","url":null,"abstract":"<p><strong>Background: </strong>Patients with multiple sclerosis (MS) receiving disease-modifying therapies (DMT) show published adherence rates of 27.0% to 93.8% and published persistence rates of 49.7% to 96.5%. Improvements in DMT adherence and persistence are key to optimizing MS care, and enhanced understanding could improve MS disease management and identify research gaps. This scoping literature review aims to examine the nature and findings of the literature evaluating factors associated with DMT adherence and persistence in patients with MS.</p><p><strong>Methods: </strong>Eligible articles included in the literature review were quantitative clinical studies written in English, included adherence or persistence as primary outcomes, and accounted for covariates/confounders. The articles were assessed to identify factors associated with adherence/persistence and analyzed according to DMT type (self-injectable, oral, infusion).</p><p><strong>Results: </strong>Fifty-eight studies (103,450 patients) were included. Study distribution by DMT type was self-injectable only (n = 41), oral only (n = 2), infusion only (n = 1), and more than 1 type (n = 14). Older age and previous DMT use were associated with increased adherence and/or persistence. Increased alcohol consumption, DMT adverse events, higher education, and higher body mass index were negatively associated with adherence and/or persistence. Greater number and severity of relapses was associated with increased adherence but decreased persistence.</p><p><strong>Conclusions: </strong>Most studies examined factors associated with adherence and persistence to self-injectable DMTs. These factors should be evaluated further for oral and infusion DMTs. Insights into the modifiable factors associated with adherence and persistence could guide treatment decisions and help improve adherence and clinical outcomes.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"188-195"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503813/pdf/i1537-2073-25-5-188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action.","authors":"Carrie M Hersh,&nbsp;Sarah A Morrow,&nbsp;Mitzi Joi Williams,&nbsp;Lilyana Amezcua,&nbsp;June Halper,&nbsp;Katherine Wandersee","doi":"10.7224/1537-2073.2023-039","DOIUrl":"10.7224/1537-2073.2023-039","url":null,"abstract":"<p><p>Many medical organizations have begun to confront the longstanding problem of inequalities in health care delivery and the undeniable effect of disparities on health outcomes. The Consortium of Multiple Sclerosis Centers (CMSC) recognizes that disparities affect the lives of many people with multiple sclerosis (MS) and acknowledges the need to address this as an organization. The CMSC recently (1) appointed a task force, (2) conducted a survey of its membership, (3) commissioned this review article and call to action, and (4) formulated a mission statement on diversity, equity, and inclusion (DEI), which was adopted by the CMSC's Board of Governors in March 2023. This paper summarizes recent literature on health care disparities in MS, particularly those relating to race/ethnicity, sexual orientation, and gender identity. It presents findings from CMSC's survey of members' awareness of DEI issues, the need for education and resources for MS care providers, and existing institutional policies on DEI in the members' practice settings. It also presents the task force's recommendations for next steps, which includes the goal of greater diversity in the MS workforce of the future. The CMSC will continue to revisit DEI policies and practices over time with the goal of motivating greater awareness, momentum, and positive changes within the MS community.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"199-205"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503818/pdf/i1537-2073-25-5-199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital Readmission Rates in Patients With Neuromyelitis Optica Spectrum Disorder.","authors":"Akhil Padarti,&nbsp;Amod Amritphale,&nbsp;William Kilgo","doi":"10.7224/1537-2073.2022-049","DOIUrl":"10.7224/1537-2073.2022-049","url":null,"abstract":"<p><strong>Background: </strong>Neuromyelitis optica spectrum disorder (NMOSD) is an aggressive central nervous system astrocytopathy often resulting in rapid neurologic decline. Patients have recurrent flares that require immunomodulatory therapy for relapse prevention. These patients are usually hospitalized and may need rehospitalization after decline. Hospital readmission rates are important indicators that can be used to gauge health care quality and have direct implications on hospital compensation. This study aims to identify high-risk characteristics of patients with NMOSD that can be used to predict hospital readmissions.</p><p><strong>Methods: </strong>The 2017 Nationwide Readmissions Database was searched for hospital admissions for NMOSD in the United States. All patients with hospital readmission within 30 days of discharge from the index hospitalization were included.</p><p><strong>Results: </strong>The 30-day all-cause readmission rate for NMOSD was 11.9% (95% CI, 10.6%-13.3%). Patients aged 65 to 74 years had higher odds of readmission; those with private insurance had decreased odds. Sex did not affect readmission. Several comorbidities, such as respiratory failure, peripheral vascular disease, neurocognitive disorders, and neurologic blindness, were predictive of readmissions. Plasma exchange increased the odds of readmission, whereas intravenous immunoglobulin and immunomodulatory infusions, such as chemotherapies and monoclonal antibodies, did not affect readmission.</p><p><strong>Conclusions: </strong>The most common etiologies for 30-day read-mission were neurologic, infectious, and respiratory. Treatment targeted toward these etiologies may result in reduced overall readmission, thereby decreasing overall disease burden.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"221-225"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503814/pdf/i1537-2073-25-5-221.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovations in Multiple Sclerosis Care: The Impact of Artificial Intelligence via Machine Learning on Clinical Research and Decision-Making.","authors":"Jacob Cartwright,&nbsp;Kristof Kipp,&nbsp;Alexander V Ng","doi":"10.7224/1537-2073.2022-076","DOIUrl":"10.7224/1537-2073.2022-076","url":null,"abstract":"<p><p>Artificial intelligence (AI) and its specialized subcomponent machine learning are becoming increasingly popular analytic techniques. With this growth, clinicians and health care professionals should soon expect to see an increase in diagnostic, therapeutic, and rehabilitative technologies and processes that use elements of AI. The purpose of this review is twofold. First, we provide foundational knowledge that will help health care professionals understand these modern algorithmic techniques and their implementation for classification and clustering tasks. The phrases <i>artificial intelligence</i> and <i>machine learning</i> are defined and distinguished, as are the metrics by which they are assessed and delineated. Subsequently, 7 broad categories of algorithms are discussed, and their uses explained. Second, this review highlights several key studies that exemplify advances in diagnosis, treatment, and rehabilitation for individuals with multiple sclerosis using a variety of data sources-from wearable sensors to questionnaires and serology-and elements of AI. This review will help health care professionals and clinicians better understand AI-dependent diagnostic, therapeutic, and rehabilitative techniques, thereby facilitating a greater quality of care.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 5","pages":"233-241"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503815/pdf/i1537-2073-25-5-233.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10672501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Climate Change and the Urgent Need to Prepare Persons With Multiple Sclerosis for Extreme Hurricanes.","authors":"Sharon L Hsieh,&nbsp;James M Shultz,&nbsp;Farren Briggs,&nbsp;Zelde Espinel,&nbsp;Lauren T Shapiro","doi":"10.7224/1537-2073.2022-032","DOIUrl":"10.7224/1537-2073.2022-032","url":null,"abstract":"<p><p>Climate change is contributing to increasingly hazardous tropical cyclones that endanger persons living in susceptible coastal and island communities. People living with chronic illness, including multiple sclerosis (MS), face unique challenges and vulnerabilities when exposed to hurricane hazards. Disaster and emergency preparedness requires a customized approach that considers the necessary adaptations to accommodate the mobility, self-care, sensory, cognitive, and communication impairments of persons living with MS. Related considerations include the potential for worsening neurologic signs and symptoms during and after a catastrophic storm. The impact of emotional and financial stresses, as well as disruptions in health care delivery, on this population are also key concerns. This paper addresses the challenges faced by individuals with MS in advance of, during, and in the aftermath of extreme storms. We propose new guidelines on how health care professionals can assist persons with MS when creating tailored disaster readiness and response plans.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 4","pages":"152-156"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353692/pdf/i1537-2073-25-4-152.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece.","authors":"Christos Bakirtzis,&nbsp;Ioannis Nikolaidis,&nbsp;Marina-Kleopatra Boziki,&nbsp;Eleni Grigoriadou,&nbsp;Maria-Valeria Karakasi,&nbsp;Theodoros Moysiadis,&nbsp;Evangelia Kesidou,&nbsp;Georgios Papazisis,&nbsp;Nikolaos Grigoriadis","doi":"10.7224/1537-2073.2022-046","DOIUrl":"10.7224/1537-2073.2022-046","url":null,"abstract":"<p><strong>Background: </strong>Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database.</p><p><strong>Methods: </strong>Prescription records for 21,218 people (65.9% women) with MS were included in the study. The criterion for study inclusion was a minimum of 3 months of continuous prescription of an agent. Identified treatments were further examined by age group.</p><p><strong>Results: </strong>Antispasticity agents (17.5%) and fampridine (14.5%) were the most regularly prescribed symptomatic medications. Antihypertensives (21.1%) and drugs for affective disorders, including antidepressants (36.1%) and anxiolytics (16.2%), were the most frequently prescribed medications for comorbid conditions. Antidepressants were prescribed at almost equally high rates among individuals older than 40 years. Hypertension was one of the leading comorbidities among the study sample, with rates rising significantly after age 40 years and plateauing after age 60 years. Polypharmacy was observed in 22.5% of the study sample, with a higher incidence among people with MS older than 60 years (46.98%).</p><p><strong>Conclusions: </strong>Agents prescribed for the treatment of disease symptoms and other medical conditions are expected to positively affect quality of life in people with MS. However, polypharmacy seems to be particularly high, especially in the aged population. The potential implications of polypharmacy in the disease course should further be explored.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 4","pages":"140-144"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353693/pdf/i1537-2073-25-4-140.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploratory Study of Community Mobility in Adults With Multiple Sclerosis Across Different Ambulation Levels.","authors":"Carley Giroux,&nbsp;Barbara Sogoloff,&nbsp;Lance Bergmans,&nbsp;Myeongjin Bae,&nbsp;Michael Vannostrand,&nbsp;Susan L Kasser","doi":"10.7224/1537-2073.2022-042","DOIUrl":"10.7224/1537-2073.2022-042","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to identify differences in community mobility in adults with multiple sclerosis (MS) at various ambulation levels.</p><p><strong>Methods: </strong>Seventy-one adults with MS completed a survey about their mobility impairment and avoidance of challenging mobility tasks. Individuals were categorized as having mild, moderate, or severe gait impairment.</p><p><strong>Results: </strong>Participants across the different functional groups significantly differed in perceived ambulation disability, fatigue impact, falls efficacy, quality of life, challenges with dual-tasking, and self-efficacy for community mobility. There were no significant differences between the mild and moderate gait impairment groups in crossing a busy street or going out in different ambient conditions. Significant differences were found between those with mild impairment and those with severe impairment in avoidance of various terrain elements, heavy manual doors, postural transitions, attentional situations, and crowded places. The only environmental dimension that significantly differed across all 3 groups was carrying 2 or more items, in which avoidance increased as ambulation worsened.</p><p><strong>Conclusions: </strong>Avoidance behavior for particular environmental features can begin relatively early in the disease process. This underscores the need to further study mobility differences, community ambulation, and participation restrictions in adults with MS.</p>","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 4","pages":"145-151"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353691/pdf/i1537-2073-25-4-145.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9834659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rest-Activity Rhythm, Pain, and Motor Activity in Multiple Sclerosis.","authors":"Rogier J Scherder,&nbsp;M J van Dorp,&nbsp;A J Prins,&nbsp;C van Klaveren,&nbsp;I Cornelisz,&nbsp;J Killestein,&nbsp;Henry C Weinstein","doi":"10.7224/1537-2073.2021-030","DOIUrl":"10.7224/1537-2073.2021-030","url":null,"abstract":"BACKGROUND\u0000Although the relationships among physical disability, mood disorders, and pain are well described in multiple sclerosis (MS), little is known about whether those symptoms are associated with sleep disturbances.\u0000\u0000\u0000METHODS\u0000Forty-six patients with MS experiencing pain participated. Sleep was indirectly measured by assessing rest-activity rhythm via actigraphy: interdaily stability, intradaily variability, and relative amplitude. Pain was assessed using visual and verbal analog scales, mood by the Beck Depression Inventory and Symptom Checklist-90, and physical disability by the Expanded Disability Status Scale.\u0000\u0000\u0000RESULTS\u0000Incorporating mood, pain, and physical disability into 1 regression model resulted in a significant association with interdaily stability.\u0000\u0000\u0000CONCLUSIONS\u0000Compared with intradaily variability and relative amplitude, interdaily stability seems to be the most vulnerable actigraphy variable for mood disturbances, pain, and physical disabilities.","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"25 4","pages":"157-162"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353695/pdf/i1537-2073-25-4-157.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9834660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}